Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
42292-0007-10 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 15, 2016 Jan. 31, 2020 No Longer Used
68682-0002-60 68682-0002 Bexarotene Bexarotene 1.0 g/100g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical June 28, 2000 In Use
69238-2088-06 69238-2088 Bexarotene Bexarotene 10.0 mg/g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical May 4, 2022 In Use
70121-1754-01 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1754-07 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
00069-0315-01 00069-0315 Bevacizumab-bvzr Zirabev 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00069-0342-01 00069-0342 Bevacizumab-bvzr Zirabev 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
55513-0206-01 55513-0206 Bevacizumab-awwb MVASI 100.0 mg/4mL, 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
50242-0060-01 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Feb. 26, 2004 In Use
50242-0060-10 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous April 1, 2019 Jan. 31, 2023 In Use
50242-0061-01 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Feb. 26, 2004 In Use
50242-0061-10 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous April 1, 2019 Feb. 28, 2023 In Use
16729-0250-03 16729-0250 Bendamustine hydrochloride Bendamustine hydrochloride 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
16729-0251-05 16729-0251 Bendamustine hydrochloride Bendamustine hydrochloride 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
10019-0079-01 10019-0079 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
63459-0348-04 63459-0348 Bendamustine Hydrochloride Bendeka 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 8, 2015 In Use
63459-0390-08 63459-0390 Bendamustine Hydrochloride Treanda 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 5, 2010 In Use
63459-0391-20 63459-0391 Bendamustine Hydrochloride Treanda 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 31, 2008 In Use
67457-0325-12 67457-0325 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 26, 2018 Feb. 21, 2019 In Use
67457-0326-05 67457-0326 Bendamustine Hydrochloride Bendamustine Hydrochloride 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 26, 2018 Feb. 21, 2019 In Use
42367-0521-25 42367-0521 Bendamustine Hydrochloride BELRAPZO 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 3, 2019 In Use
63459-0395-02 63459-0395 Bendamustine Hydrochloride Treanda 45.0 mg/.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 5, 2014 April 30, 2017 No Longer Used
63459-0396-02 63459-0396 Bendamustine Hydrochloride Treanda 180.0 mg/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 5, 2014 May 31, 2017 No Longer Used
68152-0108-09 68152-0108 Belinostat Beleodaq 500.0 mg/10mL Chemotherapy Enzyme Inhibitor HDAC Intravenous July 21, 2014 Nov. 30, 2022 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug. 5, 2020 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70710-1411-01 70710-1411 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
00409-0323-20 00409-0323 BLEOMYCIN Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 25, 2018 In Use
70255-0010-02 70255-0010 BINIMETINIB MEKTOVI 15.0 mg/1 Chemotherapy MEK Inhibitor MEK 1/2 Oral June 27, 2018 In Use
70255-0010-03 70255-0010 BINIMETINIB MEKTOVI 15.0 mg/1 Chemotherapy MEK Inhibitor MEK 1/2 Oral June 27, 2018 In Use
71225-0120-01 71225-0120 BENDAMUSTINE HYDROCHLORIDE VIVIMUSTA 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
49281-0880-03 49281-0880 BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN THERACYS 81.0 mg/3mL Immunotherapy Biological Response Modifier Live Vaccine Intravesical July 22, 2011 May 8, 2017 No Longer Used
00052-0602-02 00052-0602 BACILLUS CALMETTE-GUERIN TICE BCG 50.0 mg/50mL Immunotherapy Biological Response Modifier Live Vaccine Intravesical Aug. 24, 1990 In Use
13925-0523-01 13925-0523 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 17, 2017 Feb. 13, 2018 No Longer Used
00143-9606-01 00143-9606 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 8, 2020 In Use
16714-0927-01 16714-0927 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 8, 2019 In Use
43817-0906-01 43817-0906 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous May 6, 2019 In Use
71288-0153-95 71288-0153 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 2, 2020 In Use
00781-9253-94 00781-9253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 27, 2014 In Use
43598-0305-62 43598-0305 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 19, 2013 In Use
43598-0465-62 43598-0465 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 19, 2015 In Use
59572-0102-01 59572-0102 Azacitidine Vidaza 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous July 5, 2004 In Use
63323-0771-39 63323-0771 Azacitidine Azacitidine 100.0 mg/30mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 16, 2017 In Use
64679-0096-01 64679-0096 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 29, 2016 In Use
68001-0313-56 68001-0313 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous July 1, 2017 In Use

Found 9,752 results in 24 milliseconds — Export these results